Bundesamt für Sicherheit im Gesundheitswesen
BASG

Update on investigational ATMP concept paper guideline

Ilona Reischl, PhD
Institute Surveillance
Federal Office for Safety in Health Care
Austrian Agency for Health and Food Safety
Traisengasse 5; 1200 Vienna, Austria

London, Dec. 2016

Starting point

- The Clinical Trials Regulation is nearing its practical application leading to a general revision of guidance documents
- An increasing number of ATMPs is under development and entering clinical trials
- While there is existing guidance for small molecules and biologics, there is none currently available for ATIMPs

  → To amend this, the EC has asked the CAT to draft specific guidance for ATIMPs
- Work started at the beginning of 2016
- National clinical trials assessors have been invited to participate via the CTFG

Current status for ATIMPs

Bundesamt für Sicherheit im Gesundheitswesen
BASG

- Cell-based medicinal products
  - No guidance
- Gene therapy medicinal products
  - Guideline on the non-clinical studies required before first clinical use of gene therapy medicinal products (EMEA/CHMP/GTWP/125459/2006)
- Guideline on strategies to identify and mitigate risks for First-in-human clinical trials with IMPs
  - ... applies to all new chemical and biological IMPs except gene and cell therapy MPs (EMEA/CHMP/SWP/28367/07)

Clinical Trials Regulation –
ATMP references

Bundesamt für Sicherheit im Gesundheitswesen
BASG

- rMS **may** extend time period for a further 50 days for CTs involving an ATMP or MPs defined in point 1 of the Annex to Regulation (EC) No 726/2004 to consult with experts
- In such case other time periods shall apply mutatis mutandis

- MPs developed by one of the following biotechnological processes:
  - recombinant DNA technology
  - controlled expression of genes coding for biologically active proteins in prokaryotes and eukaryotes including
  - transformed mammalian cells
  - hybridoma and monoclonal antibody methods

CT Regulation
ATMP references

Bundesamt für Sicherheit im Gesundheitswesen
BASG

- *Art 90 Specific requirements for special groups of medicinal products*

This Regulation shall not affect the application of national law prohibiting or restricting the use of any specific type of human or animal cells, or the sale, supply or use of medicinal products containing, consisting of or derived from those cells, …
The MSs shall communicate that national law to the Commission.
No gene therapy clinical trials may be carried out which result in modifications to the subject's germ line genetic identity

- *Art. 91 Relation with other Union legislation*

..shall be without prejudice to .. Dir/2001/18/EC (deliberate release), Dir/2009/41/EC (contained use), Dir/2004/23/EC (T&C), Dir/2002/98/EC (blood), Dir/2010/53/EC (transplantation)

Current Guidance

European Medicines Agency

London, 21 May 2008
Doc. Ref. EMEA/CHMP/410869/2006

COMMITTEE FOR MEDICINAL PRODUCT FOR HUMAN USE (CHMP)	
GUIDELINE ON HUMAN CELL-BASED MEDICINAL PRODUCTS	
DATE FOR COMING INTO EFFECT	1 September 2008

Guidance for Industry

Potency Tests for Cellular and Gene Therapy Products

European Medicines Agency
Evaluation of Medicines for Human Use

London, 10 October 2007
Doc. Ref. EMEA/CHMP/BWP/271475/2006

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)	
GUIDELINE ON POTENCY TESTING OF CELL BASED IMMUNOTHERAPY MEDICINAL PRODUCTS FOR THE TREATMENT OF CANCER	
DATE FOR COMING INTO EFFECT	15 May 2008

14 January 2011
EMA/CAT/571134/2009
Committee for Advanced Therapies (CAT)

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Reflection paper on stem cell-based medicinal products

Adoption by CAT	14 January 2011

London, 08 April 2010
EMA/CAT/CPWP/568181/2009
Committee For Advanced Therapies (CAT)

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Reflection paper on *in-vitro* cultured chondrocyte containing products for cartilage repair of the knee

Final

Adoption by CAT	16 April 2010

Current Guidance

11 February 2013
EMA/CAT/CPWP/686637/2011
Committee for Advanced Therapies (CAT)

Guideline on the risk-based approach according to annex I, part IV of Directive 2001/83/EC applied to Advanced therapy medicinal products

Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products

---

Guidance for Industry

14 January 2011
EMA/CAT/571134/2009
Committee for Advanced Therapies (CAT)

Reflection paper on stem cell-based medicinal products

Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs)

Guidance for Human Somatic Cell Therapy and Gene Therapy

GUIDANCE DOCUMENT: Preparation of Clinical Trial Applications for use of Cell Therapy Products in Humans

Content

- Aim of alignment with current EMA guidance and taking into consideration guidance from other agencies (FDA, Health Canada)
- Intended applicability for all ATMPs, coverage of quality, non-clinical and clinical aspects

  → specific drafting groups
- Similarly to the Guidance for Biologic IMPs, the main focus is on minimal requirements for early clinical trials, but guidance for later development will also be included
- Differentiation between exploratory and pivotal clinical trials rather than phases

Content

- Text for cell-based and gene therapy products is drafted separately and will be brought together at a later stage
- Existing GI on non-clinical requirements for gene therapy products will be incorporated
- Considerations for combination products will be included

- The guidance is expected to be released for consultation during the first quarter of 2017

Thank you for your attention!

Questions?



International New York Times March 23rd , 2016